Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18451171 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Cheung M, Sharma A, Madhunapantula SV, Robertson GP (2008) Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 68, 3429-39 18451171
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S365-p - BRAF (human)
Orthologous residues
BRAF (human): S365‑p, BRAF (mouse): S348‑p, BRAF iso3 (mouse): S298‑p, BRAF (rat): S347‑p, BRAF (chicken): S365‑p, BRAF (quail): S365‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  melanoma skin cancer
 Relevant cell lines - cell types - tissues:  Melan-a (melanocyte)
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE Akt3 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt3 (human) modification site within consensus motif, transfection of inactive enzyme, transfection of constitutively active enzyme
Downstream Regulation
 Effect of modification (function):  enzymatic activity, inhibited
 Effect of modification (process):  cell growth, altered, transcription, induced

S429-p - BRAF (human)
Orthologous residues
BRAF (human): S429‑p, BRAF (mouse): S464‑p, BRAF iso3 (mouse): S362‑p, BRAF (rat): S463‑p, BRAF (chicken): S469‑p, BRAF (quail): S469‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  melanoma skin cancer
 Relevant cell lines - cell types - tissues:  Melan-a (melanocyte)
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE Akt3 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt3 (human) modification site within consensus motif, transfection of inactive enzyme, transfection of constitutively active enzyme
Downstream Regulation
 Effect of modification (function):  enzymatic activity, inhibited
 Effect of modification (process):  cell growth, altered, transcription, induced

T599-p - BRAF (human)
Orthologous residues
BRAF (human): T599‑p, BRAF (mouse): T636‑p, BRAF iso3 (mouse): , BRAF (rat): T636‑p, BRAF (chicken): T639‑p, BRAF (quail): T639‑p
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

S602-p - BRAF (human)
Orthologous residues
BRAF (human): S602‑p, BRAF (mouse): S639‑p, BRAF iso3 (mouse): , BRAF (rat): S639‑p, BRAF (chicken): S642‑p, BRAF (quail): S642‑p
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

T202-p - ERK1 (human)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  melanoma skin cancer
 Relevant cell lines - cell types - tissues:  NHEM (melanocyte), SK-MEL24 (melanocyte), UACC-903, WM35 (melanocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA Akt3 (human) no change compared to control normal melanocytes
siRNA Akt3 (human) increase melanoma cells
LY294002 increase melanoma cells
Akt3 (human) decrease activated, melanoma cells

Y204-p - ERK1 (human)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  melanoma skin cancer
 Relevant cell lines - cell types - tissues:  NHEM (melanocyte), SK-MEL24 (melanocyte), UACC-903, WM35 (melanocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA Akt3 (human) no change compared to control normal melanocytes
siRNA Akt3 (human) increase melanoma cells
LY294002 increase melanoma cells
Akt3 (human) decrease activated, melanoma cells

T185-p - ERK2 (human)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  melanoma skin cancer
 Relevant cell lines - cell types - tissues:  NHEM (melanocyte), SK-MEL24 (melanocyte), UACC-903, WM35 (melanocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA Akt3 (human) no change compared to control normal melanocytes
siRNA Akt3 (human) increase melanoma cells
LY294002 increase melanoma cells
Akt3 (human) decrease activated, melanoma cells

Y187-p - ERK2 (human)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  melanoma skin cancer
 Relevant cell lines - cell types - tissues:  NHEM (melanocyte), SK-MEL24 (melanocyte), UACC-903, WM35 (melanocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA Akt3 (human) no change compared to control normal melanocytes
siRNA Akt3 (human) increase melanoma cells
LY294002 increase melanoma cells
Akt3 (human) decrease activated, melanoma cells


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.